NVE is trading at $71.96, down 30.14%, after fiscal second-quarter results disappointed investors.
- Revenue was $5.83 million, down 8% year over year; diluted EPS was $0.65, versus $0.68 a year earlier.
- Lower product sales drove the revenue decline, including sharp weakness in defense sales and the timing of a medical-device customer’s order.
- First-half revenue rose 36%, but concern over the quarterly decline and near-term sales visibility persisted amid a weaker market backdrop.